Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nedaplatin + vindesine
- Development stage
- Unknown
- Lead developer
- Shionogi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of nedaplatin, a second-generation platinum derivative, and vindesine, a vinca alkaloid. Nedaplatin works by binding to DNA bases and inhibiting DNA replication, similar to other platinum compounds but with less nephrotoxicity and gastrointestinal toxicity. Vindesine acts as a microtubule inhibitor, disrupting cell division. This combination has been studied primarily for the treatment of non-small-cell lung cancer (NSCLC).
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nedaplatin + vindesine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nedaplatin + vindesine.